SEO URLwww.firestrike.ai/deals/corstasis-therapeutics-esperion-acquisition-2026-4

acquisitionAnnounced · Mar 4, 2026BiopharmaceuticalSource · MagazinesArticle · Factual

Corstasis Therapeutics · Esperion

Esperion acquires Corstasis Therapeutics

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

—

Target

Corstasis Therapeutics

Henderson, Nevada

Acquirer

Esperion

Full Acquisition

Status

Pending

Esperion agreed to acquire Corstasis Therapeutics. Reported deal value: Undisclosed. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: Henderson, Nevada, United States.

This page summarizes publicly available information about the transaction as of 2026-03-04. Figures and status may change as filings and press coverage update.

Today at 4:07 AM Esperion Therapeutics : $ 75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics , a commercial-stage biopharmaceutical company focused on therapies for fluid overload conditions, in a transaction that includes an upfront cash payment of $ 75 million and potential milestone payments of up to $1 80 million

Deal timeline

Announced

Mar 4, 2026 · pulse2.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in Biopharmaceutical. Figures and status may change as sources update.

Sources: pulse2.com · Primary article · FireStrike proprietary index